EUCTR2015-005105-36-IT进行中（未招募）1 期
An Open-label study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed orRelapsed and Refractory Multiple Myeloma - A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients
PHARMACYCLICS, INC.0 个研究点目标入组 74 人开始时间: 2018年2月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects with MM who have received 1-3 prior lines of therapy and have demonstrated disease progression since the completion of the most recent treatment regimen.
- •2. Measurable disease defined by at least ONE of the following:
- •Serum monoclonal protein (SPEP) =1 g/dL
- •Urine monoclonal protein (UPEP) =200 mg by 24 hour urine electrophoresis
- •3. Adequate hematologic function
- •4. Adequate hepatic and renal function
- •5. Prothrombin time (PT)/ International normal ratio (INR) =1.5 x upper limit of normal (ULN)
- •and PTT (activated partial thromboplastin time [aPTT]) =1.5 x ULN
- •6. Male and female =18 years of age
- •7. Eastern Cooperative Oncology Group (ECOG) performance status of =2.
- •8. Male and female subjects of reproductive potential who agree to use highly effective methods of birth control during the period of therapy and for 90 days after the last dose of study treatment. Female subjects who are of non-reproductive potential. Female subjects of reproductive potential must have a negative serum pregnancy test upon study entry.
- •Other protocol-defined inclusion criteria could apply
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 1
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Primary refractory disease defined as nonresponsive in patients who have never achieved a minimal response or better with any therapy.
- •2. History of plasma cell leukemia, primary amyloidosis, POEMS syndrome within 12 months prior to first administration of study treatment.
- •3. Recent prior chemotherapy
- •4. Prior exposure to BTK inhibitors
- •5. Refractory or non-responsive to prior PI therapy (bortezomib or carfilzomib)
- •6. History of hypersensitivity reactions to prior bortezomib, to boron, mannitol or nitrogen.
- •7. History of other malignancies
- •8. Peripheral neuropathy Grade =2 or Grade 1 with pain at Screening
- •9. Prior allogeneic stem cell transplant
- •10. Recent infection requiring systemic treatment that was completed <7 days before the first administration of study treatment and/or uncontrolled active
- •systemic infection.
- •11. Unresolved toxicities from prior anti-cancer therapy
- •12. Known bleeding disorders (eg, von Willebrand’s disease or hemophilia)
- •13. History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
- •14. Known history of human immunodeficiency virus (HIV) or active with hepatitis C virus (HCV) or hepatitis B virus (HBV)
- •15. Major surgery within 4 weeks of first administration of study treatment.
- •16. Any life-threatening illness, medical condition, including uncontrolled Diabetes Mellitus, or organ system dysfunction
- •17. Currently active, clinically significant hepatic impairment
- •18. Currently active, clinically significant cardiovascular disease
- •19. Unable to swallow capsules or malabsorption syndrome
- •20. Subjects who received a strong cytochrome P (CYP) 450 3A inhibitor within 7 days prior to the first administration of study treatment or subjects who require continuous treatment with a strong CYP 3A
- •21. Lactating or pregnant
- •Other protocol-defined exclusion criteria could apply
研究者
相似试验
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsEUCTR2015-005105-36-CZPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 19.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-PLPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 19.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-GRPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 19.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-ESPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 20.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-DEPharmacyclics Switzerland GmbH125